Head-to-head evidence
AZD0449 vs AZD4604
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: JAK1 · full Asthma pipeline
AZD0449
Developed by AstraZeneca
NCT03766399 · Phase 1 · completed
Participants were randomized to AZD0449 or placebo with blinding maintained across most of the many dose cohorts, but the trial's primary measures were safety and drug-level data rather than an asthma outcome, and adverse events were only reported as counts with no formal statistical test. Nearly all reported adverse events were mild, with none serious and no deaths in any of the sixteen study groups.
AZD4604
Developed by AstraZeneca
NCT06020014 · Phase 2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 339 participants enrolled. Its primary endpoint was time to the first CompEx Asthma event, a composite surrogate measure, and results are not posted, so whether the primary comparison was met or missed is unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD0449's landscape · AZD4604's landscape